BazEkon - Biblioteka Główna Uniwersytetu Ekonomicznego w Krakowie

BazEkon home page

Meny główne

Autor
Wcisło Jacek (Phoenics MA), Kocic Ivan (Medical University of Gdansk), Kawalec Paweł (Collegium Medicum Jagiellonian University, Cracow, Poland; HTACenter, Cracow, Poland)
Tytuł
Clinical Effectiveness Analisis of LMWH in the Prevention of Deep Vein Thrombosis and Pulmonary Embolism
Źródło
Journal of Health Policy and Outcomes Research, 2013, nr 1, s. 126-139, rys., tab., bibliogr. 48 poz.
Słowa kluczowe
Zdrowie, Choroby
Health, Illness
Uwagi
summ.
Abstrakt
Background: The aim of the study was to assess the clinical effectiveness of low molecular weight heparins in prevention of deep vein thrombosis and pulmonary embolism in comparison with physical methods, unfractionated heparin and placebo, by a systematic review of reports in medical literature. Methods: The assessment of the clinical effectiveness of undertaken interventions was compliant with the principles of systematic review (EBM), based on the Cochrane Collaboration guidelines. Statistical analysis and meta-analysis were performed by means of the RevMan 4.2 software version. Results: Regarding the risk of postoperative overall deep-vein thrombosis and proximal deep-vein thrombosis, a meta-analysis of obtained results revealed a trend towards low-molecular-weight heparin versus the results of physical methods. However, the difference between the analyzed groups did not reach statistical significance. Compared to placebo, the results of deep vein thrombosis risk assessment by meta-analysis showed statistically significant differences in favor of low-molecular-weight heparins (RR = 0.50, 95% CI: 0.34, 0.74, P = 0.0004, NNT = 23). In comparison to the group, receiving unfractionated heparin, the observed differences did not attain statistical significance, neither in thromboembolism prevention nor in deep vein thrombosis treatment. Regarding the risk of any bleeding episodes, the meta-analysis showed a statistically significant difference in favor of low-molecular-weight heparins administered in the study group vs. placebo results in the control group (RR = 1.55, 95% CI: 1.07, 2.24, P = 0.02) with the NNH equal to 94. Conclusion:Low molecular weight heparins are effective and safe treatment for venous thromboembolism versus placebo, however, no statistically significant advantages were observed vs. physical methods or unfractionated heparins.(original abstract)
Pełny tekst
Pokaż
Bibliografia
Pokaż
  1. Warwick D., Harrison J., Whitehouse S., Mitchelmore A., Thornton M. A randomised comparison of a foot pump and low-molecular-weight heparin in the prevention of deep-vein thrombosis after total knee replacement. J Bone Joint Surg Br. 2002 Apr;84(3):344 - 50
  2. Warwick D., Harrison J., Glew D., Mitchelmore A., Peters TJ., Donovan J. Comparison of the use of a foot pump with the use of low-molecular-weight heparin for the prevention of deep-vein thrombosis after total hip replacement. A prospective, randomized trial. J Bone Joint Surg Am. 1998 Aug; 80(8):1158-66
  3. Norgren L., Toksvig-Larsen S., Magyar G., Lindstrand A., Albrechtsson U. Prevention of deep vein thrombosis in knee arthroplasty: preliminary results from a randomised controlled study of lowmolecular weight heparin vs foot pump compression. Int Angiol1998; 17:93-6
  4. Blanchard J., Meuwly JY., Leyvraz PF., et al. Prevention of deep vein thrombosis after total knee replacement: randomised comparison between a low-molecular-weight heparin (nadroparin) and mechanical prophylaxis with a foot-pump system. J Bone Joint Surg [Br] 1999; 81-B:654-9
  5. Verso M. et al. Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol. 2005 Jun 20; 23(18): 4057-62. Epub 2005 Mar 14
  6. Leizorovicz A. et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004 Aug 17; 110(7): 874-9. Epub 2004 Aug 2
  7. Fraisse F. et al. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The Association of Non-University Affiliated Intensive Care Specialist Physicians of France. Am J Respir Crit Care Med. 2000 Apr; 161(4 Pt 1): 1109-14
  8. Leclerc J.R. et al. Prevention of deep vein thrombosis after major knee surgery-a randomized, double-blind trial comparing a low molecular weight heparin fragment (enoxaparin) to placebo. Thromb Haemost. 1992 Apr 2; 67(4): 417-23
  9. Sherman D.G. et al. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomised comparison. Lancet. 2007 Apr 21; 369(9570): 1347-55
  10. Hillbom M. et al. Enoxaparin vs heparin for prevention of deep-vein thrombosis in acute ischaemic stroke: a randomized, double-blind study. Acta Neurol Scand 2002; 106:84-92
  11. Kleber F.X. et al. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. THE-PRINCE Study Group. American Heart Journal 2003; 145 (4): 614-21
  12. Bergmann J.F. e al. A multicenter randomized double - blind study of enoxaparin compared with unfractioned heparin in prevention of venous thromboembolic disease in elderly in-patients bedridden for ana acute medical illness. Verlagsgesellschaft mbH 1996; 76 (4): 529-34
  13. Nurmohamed M.T. et al. A comparative trial of a low molecular weight heparin (enoxaparin) versus standard heparin for the prophylaxis of postoperative deep vein thrombosis in general surgery. Am J Surg. 1995 Jun; 169(6): 567-71
  14. McLeod R.S. et al. Subcutaneous Heparin Versus Low Molecular Weight Heparin as Thromboprophylaxis in Patients Undergoing Colorectal Surgery. ANNALS OF SURGERY Vol. 233, No. 3, 438-444
  15. Colwell C.W. Jr. et al. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep venous thrombosis after elective knee arthroplasty. Enoxaparin Clinical Trial Group. Clin Orthop Relat Res. 1995 Dec; (321): 19-27
  16. Colwell C.W. Jr et al. Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. A clinical trial comparing efficacy and safety. Enoxaparin Clinical Trial Group. J Bone Joint Surg Am. 1994 Jan; 76(1): 3-14
  17. Fauno P. et al. Prophylaxis for the prevention of venous thromboembolism after total knee arthroplasty. A comparison between unfractionated and low-molecular-weight heparin. J Bone Joint Surg Am. 1994 Dec; 76(12): 1814-8
  18. Levine M.N. et al. Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Ann Intern Med. 1991 Apr 1; 114(7): 545-51
  19. Avikainen V. et al. Low molecular weight heparin (enoxaparin) compare with unfractioned heparin in prophylaxis od deep venous thrombosis and pulmonary embolism in patients undergoing hip replacement. Annales Chirurgiae et Gynaecologiae 1995; 84: 85 - 90
  20. Senaran H. et al. Enoxaparin and heparin comparison of deep vein thrombosis prophylaxis in total hip replacement patients. Arch Orthop Trauma Surg (2006); 126: 1-5
  21. Spinal Cord Injury Thromboprophylaxis Investigators. Prevention of venous thromboembolism in the acute treatment phase after spinal cord injury: a randomized, multicenter trial comparing low-dose heparin plus intermittent pneumatic compression with enoxaparin. J Trauma. 2003 Jun;54(6):1116-24; discussion 1125-6Studies not available and not included:
  22. Bernstein R.A. Prevention of venous thromboembolism in patients with stroke - enoxaparin vs unfractionated heparin. Nat Clin Pract Neurol. 2007 Sep 11; [Epub ahead of print]Studies withdrawn as not meeting inclusion criteria:
  23. Ramos J. et al. Interventions for preventing venous thromboembolism in adults undergoing knee athroscopy. Cochrane Database of Systematic Reviews 2007; Issue 2. Art. No.: CD005259
  24. Handoll HHG. et al. Heparin, low molecular weight heparin and physical methods for preventing deep vein thrombosis and pulmonary embolism following surgery for hip fractures. Cochrane Database of Systematic Reviews 2002, Issue 4. Art. No.: CD000305
  25. Mismetti P. et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost 2000; 83: 14-9
  26. Dentali F. et al. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Intern Med. 2007 Feb 20; 146(4): 278-88
  27. Vaitkus P.T. et al. Rationale and design of a clinical trial of a low-molecular-weight heparin in preventing clinically important venous thromboembolism in medical patients: the prospective evaluation of dalteparin efficacy for prevention of venous thromboembolism in immobilized patients trial. Vasc Med. 2002; 7(4): 269-73
  28. Spinal Cord Injury Thromboprophylaxis Investigators. Prevention of venous thromboembolism in the rehabilitation phase after spinal cord injury: prophylaxis with low-dose heparin or enoxaparin. J Trauma. 2003 Jun; 54(6): 1111-5
  29. Kearon C. et al. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA. 2006 Aug 23; 296(8): 935-42
  30. Marsland T. et al. Is once- or twice-a-day enoxaparin as effective as unfractionated heparin for the treatment of venous thromboembolism (VTE)? J Fam Pract. 2001 May; 50(5): 396
  31. Merli G. et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med. 2001 Feb 6; 134(3): 191-202
  32. Chong B.H. et al. Once-daily enoxaparin in the outpatient setting versus unfractionated heparin in hospital for the treatment of symptomatic deep-vein thrombosis. J Thromb Thrombolysis. 2005 Jun; 19(3): 173-8
  33. Ramacciotti E. et al. An open-label, comparative study of the efficacy and safety of once-daily dose of enoxaparin versus unfractionated heparin in the treatment of proximal lower limb deep-vein thrombosis. Thromb Res. 2004; 114(3): 149-53
  34. Levine M. et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med. 1996 Mar 14; 334(11): 677-8
  35. Monreal M. et al. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost. 1994 Jan; 71(1): 7-11
  36. Lindmarker P. et al. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost. 1994 Aug; 72(2): 186-90
  37. Koopman M.M. et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med. 1996 Mar 14; 334(11): 682-7
  38. Findik S. et al. Low-molecular-weight heparin versus unfractionated heparin in the treatment of patients with acute pulmonary thromboembolism. Respiration. 2002;69(5):440-4.
  39. Pérez de Llano L.A. et al. Multicenter, prospective study comparing enoxaparin with unfractionated heparin in the treatment of submassive pulmonary thromboembolism. Arch Bronconeumol. 2003 Aug; 39(8): 341-5
  40. Pini M. et al. Low molecular weight heparin (Alfa LHWH) compared with unfractionated heparin in prevention of deep-vein thrombosis after hip fractures. International Angiology 1989; 8: 134-9
  41. Quinlan D.J. et al. Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials. Ann Intern Med. 2004 Feb 3; 140(3): 175-83
  42. Wirth T. et al. Prevention of venous thromboembolism after knee arthroscopy with low-molecular weight heparin (Reviparin): Results of a randomized controlled trial. Arthroscopy 2001;17(4):393-9.
  43. Marlovits S. et al. A prospective, randomized, placebo-controlled study of extended-duration post-discharge thromboprophylaxis with enoxaparin following arthroscopic reconstruction of the anterior cruciate ligament. Blood 2004;104 (11 Part 1): Abstract 1764
  44. Geerts W. et al. Thromboprophylaxis after major trauma - a double-blind RCT comparing low dose Heparin (LDH) and the low molecular weight heparin (LMWH), Enoxaparin [Abstract]. Journal of Trauma 1995; 39(1): 159
  45. Grosset A.B. et al. Enoxaparin, a low-molecular-weight heparin suppresses prothrombin activation more effectively than unfractionated heparin in patients treated for venous thromboembolism. Thrombosis research 1997; 86 (5): 349-54
  46. Diener H.C. et al, for the PROTECT Trial Group. Prophylaxis of thrombotic and embolic events in acute ischemic stroke with the low-molecular-weight heparin certoparin: results of the PROTECT Trial. Stroke 2006; 37: 139-44Studies used in introduction:
  47. Chęciński P. et al. Żylna choroba zakrzepowo-zatorowa. Przew Lek 2006; 5: 54-69
  48. Filipecki S. Epidemiologia i czynniki ryzyka żylnej choroby zakrzepowo-zatorowej. Warszawa 2002; 4-10
Cytowane przez
Pokaż
ISSN
2299-1247
Język
eng
URI / DOI
http://dx.doi.org/10.7365/JHPOR.2013.3.13
Udostępnij na Facebooku Udostępnij na Twitterze Udostępnij na Google+ Udostępnij na Pinterest Udostępnij na LinkedIn Wyślij znajomemu